利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.053 秒)

    Compositions and methods for the diagnosis and treatment of immune disorders
    8.
    发明授权
    Compositions and methods for the diagnosis and treatment of immune disorders 有权
    用于诊断和治疗免疫疾病的组合物和方法

    公开(公告)号：US07972797B2

    公开(公告)日：2011-07-05

    申请号：US12284648

    申请日：2008-09-24

    申请人： Gillian A. Kingsbury ,  Kevin R. Leiby

    发明人： Gillian A. Kingsbury ,  Kevin R. Leiby

    IPC分类号： G01N33/53

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/21 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

    摘要： The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders.In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e., disorders associated with a TH2 or TH2-like mediated immune response) such as atopic conditions (e.g., allergy and asthma). Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders and for monitoring the efficacy of compounds used in clinical trials.

    摘要翻译： 本发明涉及用于治疗和诊断免疫疾病，特别是T辅助淋巴细胞相关疾病的方法和组合物。 特别地，本发明描述了本领域已知的基因，或者作为ST2，T1和Fit-1，并且在本文中称为103基因。 本文公开的103基因在TH2细胞中不差异表达，而不在TH1细胞中。 此外，103基因产物在本文中被证明是体外和体内TH2和TH2样免疫应答的重要调节剂。 因此，103基因，其基因产物和与其结合的抗体可以在诊断上用作治疗性干预的目标，用于治疗各种免疫疾病。 在这方面，本发明提供了用于鉴定和治疗用于治疗免疫疾病，特别是TH细胞亚群相关病症并包括TH2和TH2样病症（即与TH2或TH2样介导的相关的病症）的化合物的方法 免疫反应），如特应性病症（如过敏和哮喘）。 另外，提供了用于TH细胞亚群相关疾病的诊断评价和预后的方法，用于鉴定表现出这种病症倾向的受试者，用于监测接受临床评估治疗这种病症的患者，并监测所用化合物的功效 在临床试验中。

    Compositions and methods for the diagnosis and treatment of immune disorders
    9.
    发明申请
    Compositions and methods for the diagnosis and treatment of immune disorders 有权

    公开(公告)号：US20090304703A1

    公开(公告)日：2009-12-10

    申请号：US12284648

    申请日：2008-09-24

    申请人： Gillian A. Kingsbury ,  Kevin R. Leiby

    发明人： Gillian A. Kingsbury ,  Kevin R. Leiby

    IPC分类号： A61K39/395 ,  C12Q1/02 ,  G01N33/68 ,  A61P37/02

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/21 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30

    摘要： The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders.In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e., disorders associated with a TH2 or TH2-like mediated immune response) such as atopic conditions (e.g., allergy and asthma). Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders and for monitoring the efficacy of compounds used in clinical trials.